Clinigen

Clinigen is a global pharmaceutical services company trusted by over 1,000 pharma and biotech partners. With more than 35 years of experience, the company accelerates access to critical medicines at every stage of the product lifecycle.

As pathfinders,Clinigen's team of over 1,100 specialists expertly navigate the complexities of clinical trial supply, early access programs, regulatory services, and long-term commercialisation through both licensed and unlicensed pathways. Operating across five continents, Clinigen delivers innovative solutions to over 130 countries each year.

Clinigen was acquired by Triton Fund V through a Scheme of Arrangement in April 2022.

Triton was attracted to the differentiation Clinigen has created through a combination of services across the pharmaceutical product lifecycle, from clinical trials to commercialization of both licensed and unlicensed medicines. Triton intends to support Clinigen in accelerating its growth through extending its geographical reach, competing more effectively for inorganic growth opportunities, and strengthening its differentiated services and digital platform to better serve its clients, healthcare professionals, and patients.

Triton believes pharma services is a rapidly growing, resilient, and non-cyclical market, and that Clinigen is well positioned to capitalise on key industry trends like continued outsourcing, direct-to-patient clinical trials, and a growing number of biologic medicines.

Under Triton’s ownership, we look forward to helping Clinigen reach its full potential with a greater focus on long term value creation by focusing on the core business, improving cross selling, developing the digital platform further, and accelerating growth through select acquisitions.